938443-19-7

Basic information

• Product Name: 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol
• Synonyms: 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol;7-chloropyrido[2,3-d]pyriMidine-2,4(1H,3H)-dione;7-Chloropyrido[2,3-d]pyriMidin-2,4(1H,3H)-dione;7-chloro-1H-pyrido[2,3-d]pyriMidine-2,4-dione;Pyrido[2,3-d]pyriMidine-2,4(1H,3H)-dione, 7-chloro-;7-ChloroPyrido[2,3-d]pyrimidine-2,4-dione;7-Chloropyrido[2,3-d]pyrimidine-2,4(1H,3H)
• CAS NO: 938443-19-7
• Molecular Formula: C₇H₄ClN₃O₂
• Molecular Weight: 197.581
• Mol File: 938443-19-7.mol

Chemical Properties

• Appearance: /
• Density: 1.561±0.06 g/cm3 (20 ºC 760 Torr)
• Refractive Index: 1.608
• PKA: 9.06±0.20(Predicted)
• CAS DataBase Reference: 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol(938443-19-7)
• EPA Substance Registry System: 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol(938443-19-7)

Safety Data

• Hazardous Substances Data: 938443-19-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
7-Chloropyrido[2,3-d]pyrimidine-2,4-diol is used as a research compound for exploring its potential applications in the pharmaceutical industry. Its unique chemical structure and properties make it a candidate for further investigation into possible drug development and therapeutic uses.
Used in Chemical Synthesis:
In the field of organic chemistry, 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol is used as an intermediate or building block in the synthesis of more complex molecules. Its reactivity and functional groups can be utilized to create a variety of chemical products, including potential pharmaceuticals and other specialty chemicals.
Used in Material Science:
7-Chloropyrido[2,3-d]pyrimidine-2,4-diol may also find applications in material science, where its unique properties could be harnessed to develop new materials with specific characteristics. This could include applications in electronics, coatings, or other advanced materials that require novel chemical structures.
Note: Due to the limited information available about 7-Chloropyrido[2,3-d]pyrimidine-2,4-diol, the above uses are speculative and based on its classification as a pyridopyrimidine and halogenated heterocyclic compound. Further research and development are necessary to fully understand its potential applications and safety profile.

InChI:InChI=1/C7H4ClN3O2/c8-4-2-1-3-5(9-4)10-7(13)11-6(3)12/h1-2H,(H2,9,10,11,12,13)

Upstream product

• 79-37-8 oxalyl dichloride 
• 64321-24-0 2-amino-6-chloro-pyridine-3-carboxamide 

Downstream Products

• 1424432-38-1 C₂₅H₃₁N₅O₃S 
• 1009303-44-9 (3S)-4-[7-chloro-2-[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d] pyrimidin-4-yl] 3-methyl-morpholine 
• 1424432-37-0 C₂₆H₃₄N₆O₂ 
• 1424432-36-9 C₂₅H₃₂N₆O₂ 
• 1424432-35-8 C₂₆H₃₄N₆O₃ 
• 938443-29-9 7-(3-chloromethyl-4-methoxy-phenyl)-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine 

Relevant articles and documents

Pyridopyrimidine KRAS G12C mutant protein inhibitor

The invention belongs to the technical field of medicines, and particularly relates to a pyridopyrimidine KRAS G12C mutant protein inhibitor shown in a general formula (I), pharmaceutically acceptable salts, stereoisomers and deuterated substances thereof. The invention also relates to a preparation method of the compounds, and a preparation method of the pharmaceutically acceptable salts, pharmaceutical preparations and pharmaceutical compositions containing the compounds. The invention also relates to the application of the compounds, pharmaceutically acceptable salts containing the compounds, pharmaceutical preparations and pharmaceutical compositions of the compounds in treatment of cancer proliferative diseases caused by KRAS G12C mutant protein.

HETEROCYCLIC COMPOUNDS AS MTOR INHIBITORS

The present disclosure describes novel heterocyclic mTOR inhibitors and methods for preparing them. The pharmaceutical compositions comprising such mTOR inhibitors and methods of using them for treating cancer, infectious diseases, and other mTOR associated disorders are also described.

PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

Pyridine and miazines mTOR inhibitors

The invention belongs to the technical field of medicines, and particularly relates to a pyridopyrimidine mammalian target of rapamycin (mTOR) inhibitor which is shown as a general formula (I), pharmaceutically acceptable salts and stereoisomers thereof, and deuterated pyridopyrimidine mammalian mTOR inhibitors, wherein Z, Z, Z, R, R, R, X and W are defined in the specifications. The invention also relates to preparation methods for the compounds, medicinal inhibitors and medicinal compositions which contain the compounds, and the application of the compounds to preparation of medicines for treating and/or preventing post-transplant lymphoproliferative diseases which have response to inhibition of mTOR activity.

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on improving cellular potency whilst maintaining or improving other key parameters, such as aqueous solubility and margins over hERG IC50, led to the discovery of the clinical candidate AZD8055 (14). Further optimization, particularly aimed at reducing the rate of metabolism in human hepatocyte incubations, resulted in the discovery of the clinical candidate AZD2014 (21).

HETEROCYCLIC JAK KINASE INHIBITORS

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer

COMBINATION 059

This invention relates to a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to; a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor; a combination product, as defined herein, comprising a kit of parts comprising a MEK inhibitor and a mTOR-selective inhibitor; use of the combination product, as defined herein, in the treatment of cancer; a method of treating cancer comprising administering the combination product, as defined herein, to a patient. The combination product, as defined herein, and methods of the invention are also useful in the treatment of other diseases associated with the activity of MEK, and/or mTOR.

2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

There is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula (1), and the use of a compound of Formula (1) as a medicament and in the treatment of cancer

PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

There is provided compounds of formula (I), which are suitable for the treatment of cancer.